Fenwick & West represented Audentes Therapeutics, Inc. (Nasdaq: BOLD), a clinical stage biotechnology company focused on developing and commercializing gene therapy products for patients living with serious, life-threatening rare diseases, in its underwritten public offering of 5,200,000 shares of common stock at a price to the public of $29.00 per share.

BofA Merrill Lynch, J.P. Morgan Securities LLC and Cowen acted as joint book-running managers for the offering. Wedbush PacGrow acted as co-manager.

The Fenwick transaction team was led by corporate lawyers Rob Freedman, Amanda Rose, Jane Jiang and Shiva Hippely.

Login

Don’t have an account yet?

Register